hsa-mir-3131: Hsa-mir-3131 is a significantly differentially expressed miRNA that has been identified in various studies [PMC9755594] [PMC4496000] [PMC8565027] [PMC3521223] [PMC9038098] [PMC4049696] [PMC8979021] [PMC8427606]. It has been found to be downregulated in tumor-adjacent samples compared to samples without tumor tissue, suggesting its potential role as a tumor suppressor in gastric cancer (GC) [PMC4496000]. However, its low expression levels in all samples have limited its use for future clinical practice in GC patients [PMC4496000]. Hsa-mir-3131 has also been found to be differentially expressed between GC and GC-adjacent tissues, supporting the hypothesis of a GC field effect [PMC4496000]. In addition, hsa-mir-3131 has been identified as one of the downstream miRNAs of TFAP2A-AS1 and is involved in the regulation of various target genes in different cancer types, including breast, ovarian, endometrial, and colon cancers [PMC8565027] [PMC8427606]. It has been shown to be upregulated in endometrial cancer and is predicted to have oncogenic properties based on its positive effect size in SMR analysis and target gene predictions from multiple tools. However, further studies are needed to fully understand the role of hsa-mir-3131 in cancer development and progression.